EP2326724B1 - Producing methionine without n-acyl-methionine - Google Patents
Producing methionine without n-acyl-methionine Download PDFInfo
- Publication number
- EP2326724B1 EP2326724B1 EP09782063.3A EP09782063A EP2326724B1 EP 2326724 B1 EP2326724 B1 EP 2326724B1 EP 09782063 A EP09782063 A EP 09782063A EP 2326724 B1 EP2326724 B1 EP 2326724B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- methionine
- met
- acyl
- source
- nam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Not-in-force
Links
- 229930182817 methionine Natural products 0.000 title claims description 98
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 title claims description 93
- 108090000623 proteins and genes Proteins 0.000 claims description 61
- 244000005700 microbiome Species 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 35
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 claims description 33
- 238000004519 manufacturing process Methods 0.000 claims description 31
- 230000014509 gene expression Effects 0.000 claims description 30
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 26
- 239000008103 glucose Substances 0.000 claims description 26
- 229940099459 n-acetylmethionine Drugs 0.000 claims description 26
- 239000002609 medium Substances 0.000 claims description 24
- 238000009825 accumulation Methods 0.000 claims description 23
- 239000001963 growth medium Substances 0.000 claims description 22
- RBAAEQRITQHPJM-LURJTMIESA-N N-propanoyl-L-methionine Chemical compound CCC(=O)N[C@H](C(O)=O)CCSC RBAAEQRITQHPJM-LURJTMIESA-N 0.000 claims description 19
- 102000004190 Enzymes Human genes 0.000 claims description 16
- 108090000790 Enzymes Proteins 0.000 claims description 16
- 230000002829 reductive effect Effects 0.000 claims description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 13
- 101100513608 Escherichia coli (strain K12) mnaT gene Proteins 0.000 claims description 11
- 229910019142 PO4 Inorganic materials 0.000 claims description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 11
- 239000010452 phosphate Substances 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 101100485337 Bacillus subtilis (strain 168) xylB gene Proteins 0.000 claims description 10
- 101100129646 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) yncA gene Proteins 0.000 claims description 10
- 101150072344 argA gene Proteins 0.000 claims description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 9
- 239000005864 Sulphur Substances 0.000 claims description 9
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 claims description 8
- 108010003977 aminoacylase I Proteins 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 230000004048 modification Effects 0.000 claims description 7
- 238000012986 modification Methods 0.000 claims description 7
- 239000002243 precursor Substances 0.000 claims description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 6
- 230000002238 attenuated effect Effects 0.000 claims description 6
- 239000011591 potassium Substances 0.000 claims description 6
- 229910052700 potassium Inorganic materials 0.000 claims description 6
- 101001074429 Bacillus subtilis (strain 168) Polyketide biosynthesis acyltransferase homolog PksD Proteins 0.000 claims description 5
- 101000936617 Bacillus velezensis (strain DSM 23117 / BGSC 10A6 / FZB42) Polyketide biosynthesis acyltransferase homolog BaeD Proteins 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 5
- 101100488178 Escherichia coli (strain K12) yedL gene Proteins 0.000 claims description 4
- 101100213289 Escherichia coli (strain K12) yfaP gene Proteins 0.000 claims description 4
- 101100106376 Escherichia coli (strain K12) yjhQ gene Proteins 0.000 claims description 4
- WQOXQRCZOLPYPM-UHFFFAOYSA-N dimethyl disulfide Chemical compound CSSC WQOXQRCZOLPYPM-UHFFFAOYSA-N 0.000 claims description 4
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 claims description 4
- 101150052631 yjdJ gene Proteins 0.000 claims description 4
- NZIOTNYOYJRBSN-UHFFFAOYSA-N 2-(butanoylamino)-4-methylsulfanylbutanoic acid Chemical compound CCCC(=O)NC(C(O)=O)CCSC NZIOTNYOYJRBSN-UHFFFAOYSA-N 0.000 claims description 3
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 229940095054 ammoniac Drugs 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 229910000037 hydrogen sulfide Inorganic materials 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims description 2
- 229940075933 dithionate Drugs 0.000 claims description 2
- GRWZHXKQBITJKP-UHFFFAOYSA-L dithionite(2-) Chemical compound [O-]S(=O)S([O-])=O GRWZHXKQBITJKP-UHFFFAOYSA-L 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 2
- ULGJWNIHLSLQPZ-UHFFFAOYSA-N 7-[(6,8-dichloro-1,2,3,4-tetrahydroacridin-9-yl)amino]-n-[2-(1h-indol-3-yl)ethyl]heptanamide Chemical compound C1CCCC2=NC3=CC(Cl)=CC(Cl)=C3C(NCCCCCCC(=O)NCCC=3C4=CC=CC=C4NC=3)=C21 ULGJWNIHLSLQPZ-UHFFFAOYSA-N 0.000 claims 1
- 229960004452 methionine Drugs 0.000 description 99
- 238000000855 fermentation Methods 0.000 description 29
- 230000004151 fermentation Effects 0.000 description 29
- 108700023418 Amidases Proteins 0.000 description 28
- 102000005922 amidase Human genes 0.000 description 27
- 241000588724 Escherichia coli Species 0.000 description 23
- 230000001965 increasing effect Effects 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 16
- 101150086633 metAA gene Proteins 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 12
- 108091034117 Oligonucleotide Proteins 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 241000282898 Sus scrofa Species 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 8
- 229960005091 chloramphenicol Drugs 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000186226 Corynebacterium glutamicum Species 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229930027917 kanamycin Natural products 0.000 description 6
- 229960000318 kanamycin Drugs 0.000 description 6
- 229930182823 kanamycin A Natural products 0.000 description 6
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 6
- 210000001322 periplasm Anatomy 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- 241000228212 Aspergillus Species 0.000 description 5
- 229930195722 L-methionine Natural products 0.000 description 5
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 5
- 229960001570 ademetionine Drugs 0.000 description 5
- 239000006227 byproduct Substances 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 210000001723 extracellular space Anatomy 0.000 description 5
- 235000003642 hunger Nutrition 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 4
- 241000228245 Aspergillus niger Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 238000010222 PCR analysis Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 230000001131 transforming effect Effects 0.000 description 4
- 241000370685 Arge Species 0.000 description 3
- 239000002028 Biomass Substances 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108700005078 Synthetic Genes Proteins 0.000 description 3
- 102000004357 Transferases Human genes 0.000 description 3
- 108090000992 Transferases Proteins 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- -1 dithionate Chemical compound 0.000 description 3
- 101150036810 eco gene Proteins 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 230000037351 starvation Effects 0.000 description 3
- 101710109578 Acetolactate synthase 1, chloroplastic Proteins 0.000 description 2
- 101710184601 Acetolactate synthase 2, chloroplastic Proteins 0.000 description 2
- 108030006759 Acetylornithine deacetylases Proteins 0.000 description 2
- 108010032178 Amino-acid N-acetyltransferase Proteins 0.000 description 2
- 102000007610 Amino-acid N-acetyltransferase Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 101001055194 Brassica napus Acetolactate synthase 3, chloroplastic Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241001646716 Escherichia coli K-12 Species 0.000 description 2
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108010064711 Homoserine dehydrogenase Proteins 0.000 description 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
- 229910004616 Na2MoO4.2H2 O Inorganic materials 0.000 description 2
- 108700006385 OmpF Proteins 0.000 description 2
- 102000018120 Recombinases Human genes 0.000 description 2
- 108010091086 Recombinases Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 102000011929 Succinate-CoA Ligases Human genes 0.000 description 2
- 108010075728 Succinate-CoA Ligases Proteins 0.000 description 2
- 102000004523 Sulfate Adenylyltransferase Human genes 0.000 description 2
- 108010022348 Sulfate adenylyltransferase Proteins 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
- 101150094831 cysK gene Proteins 0.000 description 2
- 101150112941 cysK1 gene Proteins 0.000 description 2
- 101150029709 cysM gene Proteins 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000012262 fermentative production Methods 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- 101150077793 ilvH gene Proteins 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000003093 intracellular space Anatomy 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 150000002741 methionine derivatives Chemical class 0.000 description 2
- 239000007003 mineral medium Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 101150015622 pyk gene Proteins 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 108020000318 saccharopine dehydrogenase Proteins 0.000 description 2
- FDEIWTXVNPKYDL-UHFFFAOYSA-N sodium molybdate dihydrate Chemical compound O.O.[Na+].[Na+].[O-][Mo]([O-])(=O)=O FDEIWTXVNPKYDL-UHFFFAOYSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 108091000044 4-hydroxy-tetrahydrodipicolinate synthase Proteins 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 108010092060 Acetate kinase Proteins 0.000 description 1
- 108010049926 Acetate-CoA ligase Proteins 0.000 description 1
- 102100035709 Acetyl-coenzyme A synthetase, cytoplasmic Human genes 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108010070753 Adenosylmethionine decarboxylase Proteins 0.000 description 1
- 102000005758 Adenosylmethionine decarboxylase Human genes 0.000 description 1
- 102100040149 Adenylyl-sulfate kinase Human genes 0.000 description 1
- 108010054404 Adenylyl-sulfate kinase Proteins 0.000 description 1
- 101000889837 Aeropyrum pernix (strain ATCC 700893 / DSM 11879 / JCM 9820 / NBRC 100138 / K1) Protein CysO Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010055400 Aspartate kinase Proteins 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 241001132374 Asta Species 0.000 description 1
- 241001112741 Bacillaceae Species 0.000 description 1
- 101100290837 Bacillus subtilis (strain 168) metAA gene Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- 241000186031 Corynebacteriaceae Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 101100435903 Corynebacterium glutamicum (strain ATCC 13032 / DSM 20300 / BCRC 11384 / JCM 1318 / LMG 3730 / NCIMB 10025) aroG gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- 101100465553 Dictyostelium discoideum psmB6 gene Proteins 0.000 description 1
- 101100310802 Dictyostelium discoideum splA gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101100498063 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) cysB gene Proteins 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 101100498062 Escherichia coli (strain K12) cysK gene Proteins 0.000 description 1
- 101100420922 Escherichia coli (strain K12) sdaB gene Proteins 0.000 description 1
- 241001013691 Escherichia coli BW25113 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 108010016979 Homoserine O-succinyltransferase Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101100433987 Latilactobacillus sakei subsp. sakei (strain 23K) ackA1 gene Proteins 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010002161 N-acetylornithine deacetylase Proteins 0.000 description 1
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- GNISQJGXJIDKDJ-YFKPBYRVSA-N O-succinyl-L-homoserine Chemical compound OC(=O)[C@@H](N)CCOC(=O)CCC(O)=O GNISQJGXJIDKDJ-YFKPBYRVSA-N 0.000 description 1
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- 241000520272 Pantoea Species 0.000 description 1
- 101100462488 Phlebiopsis gigantea p2ox gene Proteins 0.000 description 1
- 108700023175 Phosphate acetyltransferases Proteins 0.000 description 1
- 108091000041 Phosphoenolpyruvate Carboxylase Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101100169519 Pyrococcus abyssi (strain GE5 / Orsay) dapAL gene Proteins 0.000 description 1
- 108010042687 Pyruvate Oxidase Proteins 0.000 description 1
- 101100386153 Rhodopirellula baltica (strain DSM 10527 / NCIMB 13988 / SH1) cysNC gene Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000204060 Streptomycetaceae Species 0.000 description 1
- 101710188371 Sulfate-binding protein Proteins 0.000 description 1
- 101100002724 Thermus thermophilus aroH gene Proteins 0.000 description 1
- 102000006843 Threonine synthase Human genes 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102100033451 Thyroid hormone receptor beta Human genes 0.000 description 1
- 108010073429 Type V Secretion Systems Proteins 0.000 description 1
- 101150015189 aceE gene Proteins 0.000 description 1
- 101150077561 aceF gene Proteins 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 101150006213 ackA gene Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 101150105638 argE gene Proteins 0.000 description 1
- 108010061206 arginine succinyltransferase Proteins 0.000 description 1
- 101150042732 aroC gene Proteins 0.000 description 1
- 101150019536 aroF gene Proteins 0.000 description 1
- 101150076125 aroG gene Proteins 0.000 description 1
- 101150018055 aroH gene Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- MPTQRFCYZCXJFQ-UHFFFAOYSA-L copper(II) chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Cu+2] MPTQRFCYZCXJFQ-UHFFFAOYSA-L 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 101150116694 cysC gene Proteins 0.000 description 1
- 101150052442 cysD gene Proteins 0.000 description 1
- 101150111114 cysE gene Proteins 0.000 description 1
- 101150086660 cysN gene Proteins 0.000 description 1
- 101150080505 cysNC gene Proteins 0.000 description 1
- 101150111924 cysZ gene Proteins 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 101150011371 dapA gene Proteins 0.000 description 1
- 230000000850 deacetylating effect Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 229910000388 diammonium phosphate Inorganic materials 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 101150097303 glyA gene Proteins 0.000 description 1
- 101150079604 glyA1 gene Proteins 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 108010071598 homoserine kinase Proteins 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 101150033780 ilvB gene Proteins 0.000 description 1
- 101150020087 ilvG gene Proteins 0.000 description 1
- 101150015635 ilvI gene Proteins 0.000 description 1
- 101150003892 ilvM gene Proteins 0.000 description 1
- 101150060643 ilvN gene Proteins 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 101150003180 metB gene Proteins 0.000 description 1
- 101150051471 metF gene Proteins 0.000 description 1
- 101150042623 metH gene Proteins 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 101150060030 poxB gene Proteins 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000001273 protein sequence alignment Methods 0.000 description 1
- 101150100525 pykA gene Proteins 0.000 description 1
- 101150053304 pykF gene Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 101150100082 sdaA gene Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 101150003830 serC gene Proteins 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 101150031436 sucD gene Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 101150072448 thrB gene Proteins 0.000 description 1
- 101150000850 thrC gene Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 108010062110 water dikinase pyruvate Proteins 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 101150065300 yncA gene Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/12—Methionine; Cysteine; Cystine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/66—Aspergillus
- C12R2001/69—Aspergillus oryzae
Definitions
- the present invention relates to a method for the production of methionine or its derivatives by culturing a microorganism in an appropriate culture medium comprising a source of carbon and a source of sulphur.
- the microorganism and/or the culture medium and/or the process parameters were modified in a way that the accumulation of the by-product N-acyl-methionine (NAM) is reduced.
- NAM N-acyl-methionine
- Sulphur-containing compounds such as cysteine, homocysteine, methionine or S-adenosylmethionine are critical to cellular metabolism and are produced industrially to be used as food or feed additives and pharmaceuticals.
- methionine an essential amino acid, which cannot be synthesized by animals, plays an important role in many body functions.
- D,L-methionine is produced by chemical synthesis from acrolein, methyl mercaptan and hydrogen cyanide.
- Increasing prices for petrol-derived precursors acrolein and methyl mercaptan coupled to the increasing methionine demand render microbial production of methionine attractive.
- Methionine produced by fermentation needs to be purified from the fermentation broth. Cost-efficient purification of methionine relies on producer strains and production processes that minimize the amount of by-products in the fermentation broth. "By-products" originate from methionine transforming and/or degrading pathways. In particular these products are S-adenosyl-methionine (SAM), thio-methyl-ribose and the N-acyl-methionines (NAM) such as N-acetyl-methionine and N-propionyl-methionine. As shown in patent application PCT/EP2007/060433 , E. coli methionine producer strains produce N-acetyl-methionine. E. coli also produces N-propionyl-methionine.
- SAM S-adenosyl-methionine
- NAM N-acyl-methionines
- NAM N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-N-N-(2-aminoethyl)-2-aminoethyl-N-N-(2-aminoethyl)-2-aminoethyl-N-N-(2-aminoethyl)-2-aminoethyl-N-N-(2-aminoethyl)-2-aminoethyl-N-N-(2-aminoethyl)-2-aminoethyl-N-N-(2-aminoethyl)-2-aminoe
- N-terminal acetylation of methionine as a co-translational process is one of the most common protein modifications in eukaryotes. Nevertheless, it is unlikely that N-acetyl-methionine is produced by N-terminal acetylases (for review see Polevoda & Sherman 2000 JBC 275, 47, pp 36479-36482 ), since methionine seems to be acetylated as a free amino acid in methionine producing bacteria and methionine acetylation as a co-translational process is rare in prokaryotes ( Driessen et al. 1985, CRC Crit. Rev. Biochem. 18, 281-325 ).
- N-acetyl-methionine is most likely obtained by acetylating free L-methionine.
- N-acetylating enzymes which possibly could acetylate methionine, have been described.
- ArgA encodes an N-acetyl-glutamate synthase in E. coli ( Marvil & Leisinger 1977 JBC 252, 10 pp. 3295-3303 ).
- NAM accumulation may also be reduced by deacetylating the accumulated NAM to obtain methionine.
- Deacetylation of N-acyl groups from amino acids has been demonstrated in bacteria.
- ArgE encoded N-acetylornithine deacetylase has a broad substrate spectrum and deacetylates efficiently N-acetylmethionine ( Javid-Majd & Blanchard 2000 Biochemistry 39, 1285-93 ).
- overexpression of argE or other amino acid deacetylases such as rat kidney acylase I ( Giardina et al 2000 Eur. J. Biochem. 267, 6249-55 ), amino acid acylase from Aspergillus niger or pig kidney ( Gentzen et al. 1980 Z. Naturforsch 35 c, 544-50 ) may reduce the accumulation of NAM.
- NAM is exported into the extracellular space
- the export of NAM acylases into the periplasm or extracellular space can be an advantage.
- Several export systems are known in E. coli that permit the export into the periplasm, for example systems TAT and Sec (reviewed in Manting & Driessen 2000 Mol Microbiol 37, 226-38 , Choi & Lee 2004 Appl. Microbiol. Biotechnol. 64, 625-635 ).
- TAT or Sec requires the presence of specific signal peptides.
- the protein of interest may be fused to carrier proteins that are normally exported into the medium, such as OmpF or hemolysin ( Choi & Lee 2004 Appl. Microbiol. Biotechnol.
- the protein can also be exported into the medium or displayed on the cell surface by fusing it to protein domains that are required for the export of autotransporter proteins, such as IgA1 from N. gonorrhoeae or AIDA-I from E. coli. Proteins may also be exported via the two-partner pathway or phage display ( Jacob-Dubuisson et al. 2004 Biochim et Biophys Act 1694 235-257 , Jose & Meyer 2007 Microbiol and Molecul Biol Rev 71, 600-19 ). Process design has also been shown to impact on the export of certain proteins ( Shokri et al 2003 Appl Microbiol Biotechnol 60, 654-64 ).
- the applicants have solved the problem of reducing the accumulation of the by-product N-acyl-methionine (NAM) in methionine producer strains.
- NAM N-acyl-methionine
- MNAT methionine N-acyltransferase activity
- a modified microorganism presenting an attenuation of the expression of the gene yncA, and therefore a reduced production of NAM, is here disclosed.
- the inventors also showed that the overexpression of deacylating enzymes, such as Aspergillus oryzae amino acid acylase or pig kidney amino acid acylase, that convert NAM to methionine, lead to a decreased amount of NAM.
- deacylating enzymes such as Aspergillus oryzae amino acid acylase or pig kidney amino acid acylase, that convert NAM to methionine, lead to a decreased amount of NAM.
- deacylating enzymes such as Aspergillus oryzae amino acid acylase or pig kidney amino acid acylase, that convert NAM to methionine
- the culture conditions were adapted to obtain a reduction of the production and/or accumulation of NAM.
- Glucose is used as a model substrate and recombinant E. coli as model organism, but the invention is not limited to these features.
- the present disclosure is related to a microorganism in which the expression of major MNAT (Methionine N-Acyl-Transferase) encoding genes have been attenuated, preferentially the corresponding genes deleted, and/or homologous or heterologous NAM deacylating enzymes have been overexpressed, to reduce the accumulation of NAM.
- major MNAT Methionine N-Acyl-Transferase
- This microorganism with decreased NAM production and/or accumulation shows an improved methionine production / carbon source yield.
- the invention relates to a method for the production of methionine, its derivatives, or precursors in a fermentative process comprising the following steps:
- the terms 'culture', 'fermentation" or “fermentative process' are used interchangeably to denote the growth of bacteria on an appropriate growth medium containing a simple carbon source.
- An "appropriate culture medium” is a medium appropriate for the culture and growth of the microorganism. Such media are well known in the art of microorganisms fermentation, depending upon the microorganism to be cultured.
- the phrase "recovering methionine and/or its derivatives from the culture medium” designates the action of recovering methionine, and possibly SAM and NAM and all other derivatives that may be useful.
- microorganism designates a bacterium, yeast or fungus.
- the microorganism is selected among Enterobacteriaceae, Bacillaceae, Streptomycetaceae and Corynebacteriaceae. More preferentially, the microorganism is a species of Escherichia, Klebsiella, Pantoea, Salmonella or Corynebacterium. Even more preferentially, the microorganism is either the species Escherichia coli or Corynebacterium glutamicum.
- modified microorganism denotes a microorganism that has been genetically modified with the goal to reduce the accumulation of NAM in the fermentation broth.
- modified microorganism denotes a microorganism that has been genetically modified with the goal to reduce the accumulation of NAM in the fermentation broth.
- Usual modifications include transforming microorganisms with genetic elements, including deletions of genes, gene replacements, modification of promoters, and introduction of vectors for the expression of heterologous genes.
- NAM is formed by acylation of methionine and have identified the gene yncA as the major NAM producing enzyme.
- yncA also known as E. coli gene b1448 has been mentioned in patent application WO2001070776 . It is part of a group of genes induced by the regulator Mar, involved in multidrug resistance.
- Amino acid acylase enzymes (EC 3.5.1.14), also called deacetylases, catalyze the hydrolytic cleavage of an acyl amino acid to produce the free amino acid and the carbonic acid corresponding to the acyl rest. More specifically N-acyl methionine acylases catalyze the reaction of NAM to methionine and the corresponding carboxy acid.
- N-acyl methionine designates N-formyl-methionine, N-acetyl-methionine, N-propionyl-methionine, N-butyryl methionine and in general, any methionine derivative comprising a functional group derived from any carboxylic acid that lacks the hydroxyl function.
- N-acetyl-methionine To measure the accumulation of N-acetyl-methionine, the amount of N-acetyl-methionine is determined in the fermentation broth using refractometric HPLC using N-acetyl-methionine (Sigma, Ref 01310) as a standard. N-propionyl-methionine is determined in the fermentation broth by GC-MS using N-acetyl-methionine as a standard.
- the accumulation of NAM should be reduced at least by 20 % preferentially 50%, more preferentially 80 % and even more preferentially 95 % of the amount accumulated in a process with the non-modified organism or in the non-modified process.
- the term 'carbon source' denotes any source of carbon that can be used by those skilled in the art to support the normal growth of a microorganism, which can be hexoses (such as glucose, galactose or lactose), pentoses, monosaccharides, disaccharides (such as sucrose, cellobiose or maltose), oligosaccharides, molasses, starch or its derivatives, hemicelluloses, glycerol and combinations thereof.
- An especially preferred carbon source is glucose.
- Another preferred carbon source is sucrose.
- the carbon source is derived from renewable feed-stock. Renewable feed-stock is defined as raw material required for certain industrial processes that can be regenerated within a brief delay and in sufficient amount to permit its transformation into the desired product.
- nitrogen source corresponds to either an ammonium salt or ammoniac gas.
- the nitrogen source is supplied in the form of ammonium or ammoniac.
- the sulphur source used for the fermentative production of L-methionine, its precursors or compounds derived thereof, may be any of the following: sulfate, thiosulfate, hydrogen sulfide, dithionate, dithionite, sulfite, methylmercaptan, dimethyldisulfide or a combination thereof.
- the sulphur source is sulfate and/or thiosulfate.
- the fermentation is generally conducted in fermenters with an appropriate culture medium adapted to the microorganism being used, containing at least one simple carbon source, and if necessary co-substrates for the production of metabolites.
- the bacteria are fermented at a temperature between 20°C and 55°C, preferentially between 25°C and 40°C, and more specifically about 30°C for C. glutamicum and about 37°C for E. coli.
- the culture medium can be of identical or similar composition to an M9 medium ( Anderson, 1946, Proc. Natl. Acad. Sci. USA 32:120-128 ), an M63 medium ( Miller, 1992; A Short Course in Bacterial Genetics: A Laboratory Manual and Handbook for Escherichia coli and Related Bacteria, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York ) or a medium such as defined by Schaefer et al. (1999, Anal. Biochem. 270: 88-96 ).
- M9 medium Anderson, 1946, Proc. Natl. Acad. Sci. USA 32:120-128
- M63 medium Miller, 1992; A Short Course in Bacterial Genetics: A Laboratory Manual and Handbook for Escherichia coli and Related Bacteria, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York
- a medium such as defined by Schaefer et al. (1999, Anal. Biochem. 270: 88-96 ).
- the culture medium can be of identical or similar composition to BMCG medium ( Liebl et al., 1989, Appl. Microbiol. Biotechnol. 32: 205-210 ) or to a medium such as described by Riedel et al. (2001, J. Mol. Microbiol. Biotechnol. 3: 573-583 ).
- the production of N-acyl-methionine is reduced by attenuating at least one of the methionine transacylases.
- Methionine transacylases are also called methionine N-acyltransferase (MNAT).
- MNAT methionine N-acyltransferase
- argA encodes an enzyme with putative methionine transacetylase activity.
- the inventors have purified MNAT activity from an E. coli strain with an argA deletion, sequenced the purified protein and shown that the purified protein, YncA has MNAT activity (patent application PCT/EP2008/060999 ).
- YncA is entirely deleted from the E. coli genome.
- N-acyltransferases with a lower activity have been identified, that permit to obtain a reduced NAM production when attenuated; these enzymes are encoded by the following genes:, yjdJ, yfaP, yedL, yjhQ. Any of the described methionine N-acyl transferases may be attenuated individually or in combination with the others.
- Attenuating a gene or 'attenuation of the expression of a gene' according to the invention denotes the partial or complete suppression of the expression of a gene, which is then said to be 'attenuated'.
- This suppression of expression can be either an inhibition of the expression of the gene, an insertion into or a deletion of all or part of the promoter region necessary for gene expression, a deletion or insertion in the coding region of the gene, or the exchange of the wildtype promoter by a weaker natural or synthetic promoter.
- the attenuation of a gene is essentially the complete deletion of that gene, which can be replaced by a selection marker gene that facilitates the identification, isolation and purification of the strains according to the invention.
- a gene is inactivated preferentially by the technique of homologous recombination ( Datsenko, K.A. & Wanner, B.L. (2000) "One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products”. Proc. Natl. Acad. Sci. USA 97: 6640-6645 ).
- N-acyl-methionine may be reduced by expressing into the microorganism native or heterologous methionine specific amino acylase enzymes, such as:
- Increased expression of methionine specific amino acylases increases the conversion rate of NAM into methionine with the concomitant production of one molecule of the corresponding carboxy acid, such as acetate, priopionate or butyrate.
- Favouring the consumption of acetate by overexpressing the genes acs, pta-ackA or genes coding for the glyoxylate shunt is also part of the invention.
- enhanced or “overexpressed” in this context describe the increase in the intracellular activity of an enzymatic activity which is encoded by the corresponding DNA, for example by increasing the number of copies of the gene, using a stronger promoter or using an allele with increased activity and possibly combining these measures.
- Chromosomally there may be one or several copies on the genome that can be introduced by methods of recombination known to the expert in the field.
- Extrachromosomally genes may be carried by different types of plasmids that differ with respect to their origin of replication and thus their copy number in the cell. They may be present as 1-5 copies, about 20 or up to 500 copies, corresponding to low copy number plasmids with tight replication (pSC101, RK2), low copy number plasmids (pACYC, pRSF1010) or high copy number plasmids (pSK bluescript II).
- the gene may be expressed using promoters with different strength, which may be inducible. These promoters may be homologous or heterologous. The man skilled in the art knows which promoters are the most convenient, for example, promoters P trc, P tac, P lac or the lambda promoter cI are widely used.
- Expression of the enzymes may be boosted or reduced by elements stabilizing or destabilizing the corresponding messenger RNA ( Carrier and Keasling (1998) Biotechnol. Prog. 15, 58-64 ) or the proteins (e.g. GST tags, Amersham Biosciences).
- elements stabilizing or destabilizing the corresponding messenger RNA Carrier and Keasling (1998) Biotechnol. Prog. 15, 58-64 ) or the proteins (e.g. GST tags, Amersham Biosciences).
- N-acyl-methionine acylase enzymes will be expressed in the intracellular space and may remain in the intracellular space or be exported into the periplasm or be exported into the extracellular space. The expert in the field will be able to identify means to target the protein to the periplasm. Export may also be based on fusing the N-acetyl-methionine acylases to proteins like OmpF, by phage display or by using protein export systems such as two-partner pathway or autotransport. In a preferred embodiment of the invention NAM acylase enzymes are exported into the periplasm or the extracellular compartment to avoid futile cycling between NAM and methionine.
- the inventors have adapted the parameters of the fermentation process, i.e. the culture conditions, to reduce the production of NAM. This is accomplished by adding into the culture medium a NAM specific acylase.
- the change of the fermentation parameters does not include the starving of the microorganism for an inorganic substrate such as phosphate, potassium, magnesium.
- the attenuation of the MNAT activity is obtained by attenuating the expression of the following genes: yncA and/or argA and/or, yjdJ, yfaP, yedL, yjhQ, these genes encoding enzymes with methionine-N-acyltransferases.
- This attenuation may be combined with the increased expression of the N-acyl-methionine deacylase enzymes, such as Aspergillus N-amino acid acylase, pig N-amino acid acylase or acetylornithine deacetylase encoded by the argE gene.
- the attenuation of at least one MNAT enzymes may be combined with adding NAM acylase to the fermentation broth, permitting together a reduction of the accumulation of NAM.
- NAM acylase enzymes may be combined with the adaptation of the process by adding NAM acylase to the fermentation broth. Details of both means have been described above.
- genes and proteins are identified using the denominations of the corresponding genes in E. coli. However, and unless specified otherwise, use of these denominations has a more general meaning according to the invention and covers all the corresponding genes and proteins in other organisms, more particularly microorganisms.
- PFAM protein families database of alignments and hidden Markov models; http://www.sanger.ac.uk/Software/Pfam/) represents a large collection of protein sequence alignments. Each PFAM makes it possible to visualize multiple alignments, see protein domains, evaluate distribution among organisms, gain access to other databases, and visualize known protein structures.
- COGs clusters of orthologous groups of proteins; http://www.ncbi.nlm.nih.gov/COG/ are obtained by comparing protein sequences from fully sequenced genomes representing major phylogenic lines. Each COG is defined from at least three lines, which permits the identification of former conserved domains.
- the means of identifying homologous sequences and their percentage homologies are well known to those skilled in the art, and include in particular the BLAST programs, which can be used from the website http://www.ncbi.nlm.nih.gov/BLAST/ with the default parameters indicated on that website.
- the sequences obtained can then be exploited (e.g., aligned) using, for example, the programs CLUSTALW (http://www.ebi.ac.uk/clustalw/) or MULTALIN (http://bioinfo.genotoul.fr/multalin/multalin.html), with the default parameters indicated on those websites.
- the present disclosure is also related to a microorganism such as described above.
- a microorganism with a reduced accumulation and/or production of N-acyl methionine is in particular useful for producing methionine with high yield.
- the microorganism is already a high-producer of methionine before being used in the process according to the invention.
- Methionine producing strains have been described in patent applications WO 2005/111202 , WO2007/077041 and PCT/EP2007/060433 .
- a methionine producing strain that overexpresses homoserine succinyltransferase alleles with reduced feed-back sensitivity to its inhibitors SAM and methionine is described in patent application WO 2005/111202 .
- This application describes also combination of these alleles with a deletion of the methionine repressor MetJ (GenBank 1790373), responsible for the down-regulation of the methionine regulon as was suggested in patent application JP 2000/157267 .
- combinations of the two modifications with the overexpression of aspartokinase/homoserine dehydrogenase are described in patent application WO 2005/111202 .
- Production of methionine may be further increased by using an altered metB allele that uses preferentially or exclusively H 2 S and thus produces homocysteine from O-succinyl-homoserine as has been described in the patent application WO 2004/076659 .
- methionine production may be obtained by deleting the genes pykA, pykF and/or purU as described in patent application PCT/EP2007/060433 .
- This application also describes methionine-producing strains in which the operons cysPUWAM, cysJIH and gcvTHP and the genes serA, serB, serC, Ipd and glyA are overexpressed.
- Anaplerotic reactions may be boosted by expressing ppc 1790393 phosphoenolpyruvate carboxylase pps 1787994 phosphoenolpyruvate synthase
- Acetate consuming reactions may be boosted by over expressing acs 1790505 acetyl-CoA synthetase
- genes in pathways degrading methionine may be attenuated or the genes may be deleted.
- Attenuation in this context describes the reduction of the intracellular activity of an enzyme by measures such as reducing its expression, reducing the stability of the enzyme, increasing its degradation and/or other solutions known to the expert in the field.
- Gene Genbank entry activity ack A 1788633 acetate kinase pta 1788635 phosphotransacetylase ace E 1786304 pyruvate deydrogenase E1 ace F 1786305 pyruvate deydrogenase E2 lpd 1786307 pyruvate deydrogenase E3 suc C 1786948 succinyl-CoA synthetase, beta subunit sucD 1786949 succinyl-CoA synthetase, alpha subunit pck 1789807 phosphoenolpyruvate carboxykinase poxB 1787096 pyruvate oxidase ilv B 1790104 acetohydroxy acid synthas
- the invention also concerns the process for the production of L-methionine, its precursors or compounds derived thereof, comprising the fermentation of the methionine producing microorganism described above, the concentration of methionine, its precursors or derivatives and the isolation of the desired product(s) of the fermentation broth.
- the bacteria are fermented at a temperature between 20°C and 55°C, preferentially between 25°C and 40°C, and more specifically about 30°C for C. glutamicum and about 37°C for E. coli.
- the fermentation is generally conducted in fermenters with an inorganic culture medium of known defined composition adapted to the bacteria used, containing at least one simple carbon source, and if necessary a co-substrate necessary for the production of the metabolite.
- the inorganic culture medium for E. coli can be of identical or similar composition to an M9 medium ( Anderson, 1946, Proc. Natl. Acad. Sci. USA 32:120-128 ), an M63 medium ( Miller, 1992; A Short Course in Bacterial Genetics: A Laboratory Manual and Handbook for Escherichia coli and Related Bacteria, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York ) or a medium such as defined by Schaefer et al. (1999, Anal. Biochem. 270: 88-96 ).
- M9 medium Anderson, 1946, Proc. Natl. Acad. Sci. USA 32:120-128
- M63 medium Miller, 1992; A Short Course in Bacterial Genetics: A Laboratory Manual and Handbook for Escherichia coli and Related Bacteria, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York
- a medium such as defined by Schaefer et al. (1999, Anal. Biochem. 270: 88-96 ).
- the inorganic culture medium for C. glutamicum can be of identical or similar composition to BMCG medium ( Liebl et al., 1989, Appl. Microbiol. Biotechnol. 32: 205-210 ) or to a medium such as described by Riedel et al. (2001, J. Mol. Microbiol. Biotechnol. 3: 573-583 ).
- the media can be supplemented to compensate for auxotrophies introduced by mutations.
- L-methionine After fermentation, L-methionine, its precursors or compounds derived thereof, is/are recovered and purified if necessary.
- the methods for the recovery and purification of the produced compound such as methionine in the culture media are well known to those skilled in the art.
- preferentially at least 90 %, more preferentially 95 %, even more preferentially at least 99% of the biomass may be eliminated during the purification of the fermentation product.
- the method for the production of methionine comprises a step of isolation of the desired amino acids/ constituents of the fermentation broth and/or the biomass optionally remaining in portions or in the total amount (0-100%) in the end product.
- Means of reducing the amount of NAM may be combined with limitation or starvation for phosphate and/or potassium.
- the expert in the field will be able to determine the amounts of phosphate or potassium necessary for growth of the chosen organism.
- Subjecting an organism to a limitation of an inorganic substrate defines a condition under which growth of the microorganisms is governed by the quantity of an inorganic chemical supplied that still permits weak growth.
- examples for these substrates are phosphate, potassium, magnesium or a combination of these.
- Starving a microorganism for an inorganic substrate defines the condition under which growth of the microorganism stops completely due to the absence of the inorganic substrate.
- examples for these substrates are phosphate, potassium, magnesium or a combination of these.
- microorganism such as described previously that is optimized for the fermentative production of methionine with a reduced accumulation of NAM, i.e. accumulating lower amounts of NAM compared to a non-modified microorganism, and the microorganism that comprises the genetic modifications described above.
- strain MG1655 met A*11 ⁇ met J Ptrc- met H Ptrc36-ARNmst17- met F PtrcF- cys PUWAM PtrcF- cys JIH ⁇ pyk A ⁇ pyk F Ptrc09-gcvTHP ⁇ pur U ⁇ ync A::Km (pME101- thr A*1- cys E-P gap A- met A*11) (pCC1BAC- ser B -ser A -ser C)
- the ⁇ ync A::Km deletion was transferred by PI phage transduction (see below) from the BW25113 ⁇ ync A::Km strain to strain MG1655 met A*11 ⁇ met J Ptrc- met H Ptrc36-ARNmst17- met F PtrcF- cys PUWAM PtrcF- cys JIH Ptrc09-gcvTHP ⁇ pyk A ⁇ pyk F ⁇ pur U (described in PCT/EP2007/060433 ).
- Kanamycine resistant transformants were selected and the insertion of the resistance cassette was verified by PCR analysis with the oligonucleotides YncAF and YncAR defined below (reference sequence on the website http://ecogene.org/ ).
- the strain retained was designated MG1655 met A*11 ⁇ met J Ptrc- met H Ptrc36-ARNmst17- met F PtrcF- cys PUWAM PtrcF- cys JIH Ptrc09-gcvTHP ⁇ pyk A ⁇ pyk F ⁇ pur U ⁇ ync A::Km.
- YncAF GTTTGCCGATTTGCCCCACCG (homologous to the ync A region from 1517564 to 1517544) (SEQ ID NO 01)
- YncAR CGCCCATCACGGTCGCAAGC (homologous to the yncA region from 1515827 to 1515846) (SEQ ID NO 02)
- Kanamycin resistant transformants were selected and the presence of the ⁇ ync A::Km modification was verified by PCR analysis with the oligonucleotides YncAF and YncAR defined above.
- strain MG1655 met A*11 ⁇ met J Ptrc -met H Ptrc36-ARNmst17- met F PtrcF- cys PUWAM PtrcF- cys JIH ⁇ pyk A ⁇ pyk F Ptrc09-gcvTHP ⁇ pur U ⁇ ync A::Km ⁇ arg A::Cm
- strain MG1655 met A*11 ⁇ met J Ptrc -met H Ptrc36-ARNmst17- met F PtrcF- cys PUWAM PtrcF- cys JIH ⁇ pyk A ⁇ pyk F Ptrc09-gcvTHP ⁇ pur U ⁇ ync A ⁇ arg A
- the pCP20 plasmid carrying recombinase FLP acting on the FRT sites of the chloramphenicol and kanamycin resistance cassettes, is introduced into the recombinant strain MG1655 met A* 11 ⁇ met J Ptrc- met H Ptrc36-ARNmst17- met F PtrcF- cys PUWAM PtrcF- cys JIH Ptrc09-gcvTHP ⁇ pyk A ⁇ pyk F ⁇ pur U ⁇ ync A::Km ⁇ arg A::Cm by electroporation.
- strain MG1655 met A*11 ⁇ met J Ptrc- met H Ptrc36-ARNmst17- met F PtrcF- cys PUWAM PtrcF-cysJIH ⁇ pyk A ⁇ pyk F Ptrc09-gcvTHP ⁇ pur U ⁇ ync A ⁇ arg A (pME101- thr A*1- cys E-P gap A- met A*11) (pCC1BAC- ser B- ser A- ser C)
- the plasmids pME101 -thr A * 1 -cys E-P gap A- met A*11 and pCC1BAC- ser B- ser A- ser C are introduced into strain MG1655 met A*11 ⁇ met J Ptrc- met H Ptrc36-ARNmst17- met F PtrcF- cys PUWAM PtrcF- cys JIH Ptrc09-gcvTHP ⁇ pyk A ⁇ pyk F ⁇ pur U ⁇ ync A ⁇ arg A giving rise to MG1655 met A*11 ⁇ met J Ptrc- met H Ptrc36-ARNmst17- met F PtrcF- cys PUWAM PtrcF- cys JIH Ptrc09-gcvTHP ⁇ pyk A ⁇ pyk F ⁇ pur U ⁇ ync A ⁇
- NAM acylases amino acid acylases
- the culture temperature was maintained constant at 37 °C and pH was maintained to the working value (6.8) by automatic addition of NH 4 OH solutions (NH 4 OH 10 % for 10 hours and 24 % until the culture end).
- the initial agitation rate was set at 200 rpm during the batch phase and was increased to up to 1200 rpm during the fed-batch phase.
- the initial airflow rate was set at 40 NL.h -1 during the batch phase and was increased to 100 NL.h -1 at the beginning of the fed-batch phase.
- Dissolved oxygen concentration was maintained at values between 20 and 40%, preferentially 30% saturation by increasing the agitation.
- Strain 1 corresponds to MG1655 met A*11 ⁇ metJ Ptrc-metH Ptrc36-ARNmst17-metF PtrcF-cysPUWAM PtrcF-cysJIH ⁇ pykA ⁇ pykF Ptrc09-gcvTHP ⁇ purU (pME101-thrA*1-cysE-PgapA-metA*11) (pCC1BAC-serB-serA-serC).
- Extracellular methionine concentration was quantified by HPLC after OPA/FMOC derivatization.
- the N-acetyl-methionine and residual glucose concentrations were analyzed using HPLC with refractometric detection.
- the N-propionyl methionine concentration was determinated by GC-MS after silylation, it was expressed as N-acetyl-methionine equivalent.
- the fermentor volume was calculated by adding to the initial volume the amount of solutions added to regulate the pH and to feed the culture and by subtracting the volume used for sampling and lost by evaporation.
- the fedbatch volume was followed continuously by weighing the feeding stock.
- the amount of injected glucose was then calculated on the basis of the injected weight, the density of the solution and the glucose concentration controlled by the method of Brix ([Glucose]).
- Y N ⁇ acetyl methionine N ⁇ acetyl methionin e t ⁇ V t Consummed g ⁇ l ⁇ u ⁇ cos e t * 100 * 0.1492 , with N-acetyl-methionine t , the concentration in mmol per liter at the instant t.
- Y N-propionyl methionine N ⁇ propionyl methionin e t ⁇ V t Consummed g ⁇ l ⁇ u ⁇ cos e t * 100 * 0.1492 with N-propionyl methionine t , the concentration in mmol per liter at the instant t.
- Y Met + NAM Methionin e t ⁇ V t + N ⁇ acetyl ⁇ methionin e t ⁇ V t ⁇ 0,1492 + N ⁇ propionyl ⁇ methionin e t * V t * 0,1492 Consummed g ⁇ l ⁇ u cos e t * 100
- Methionine t the methionine concentration in g per liter, N-acetyl-methionine t and N-propionyl-methioninet, the respective concentrations in mmol per liter at the instant t.
- N-acetyl-methionine into methionine and acetate 160 U of N-amino acid acylase (porcine kidney, Sigma) were added to 200 ⁇ l fermentation broth after the fermentation run of strain 1 (performed as described above). The reaction mixture was incubated at 37 °C for 2 h. Subsequently methionine and N-acetyl-methionine concentrations were determined as described above. 75-95 % of N-acetyl-methionine was transformed into methionine by this enzymatic treatment.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL09782063T PL2326724T3 (pl) | 2008-08-22 | 2009-08-21 | Wytwarzanie metioniny bez N-acylometioniny |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2008/061005 WO2010020290A1 (en) | 2008-08-22 | 2008-08-22 | Producing methionine without n-acetyl methionine |
US12/370,422 US8748136B2 (en) | 2008-08-22 | 2009-02-12 | Producing methionine without N-acyl-methionine |
PCT/EP2009/060811 WO2010020681A1 (en) | 2008-08-22 | 2009-08-21 | Producing methionine without n-acyl-methionine |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2326724A1 EP2326724A1 (en) | 2011-06-01 |
EP2326724B1 true EP2326724B1 (en) | 2019-05-22 |
Family
ID=40683227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09782063.3A Not-in-force EP2326724B1 (en) | 2008-08-22 | 2009-08-21 | Producing methionine without n-acyl-methionine |
Country Status (13)
Country | Link |
---|---|
US (1) | US8748136B2 (ko) |
EP (1) | EP2326724B1 (ko) |
JP (1) | JP5805533B2 (ko) |
KR (1) | KR101660060B1 (ko) |
CN (2) | CN104293845A (ko) |
AR (1) | AR073113A1 (ko) |
BR (1) | BRPI0917192A2 (ko) |
ES (1) | ES2739466T3 (ko) |
MX (1) | MX2011001962A (ko) |
MY (1) | MY174404A (ko) |
PL (1) | PL2326724T3 (ko) |
RU (1) | RU2011108705A (ko) |
WO (2) | WO2010020290A1 (ko) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5922036B2 (ja) * | 2009-12-30 | 2016-05-24 | メタボリック エクスプローラー | メチオニンの生産のための株および方法 |
AR083468A1 (es) | 2010-10-25 | 2013-02-27 | Metabolic Explorer Sa | Aumento de la disponibilidad de nadph para la produccion de metionina |
EP2468383A1 (de) * | 2010-12-22 | 2012-06-27 | Evonik Degussa GmbH | Verfahren zur thermischen Nachverbrennung von Abgasen aus der Acrolein- und aus der Blausäureherstellung |
WO2012090022A1 (en) | 2010-12-30 | 2012-07-05 | Metabolic Explorer | Fermentative production of methionine hydroxy analog (mha) |
WO2012090021A1 (en) | 2010-12-30 | 2012-07-05 | Metabolic Explorer | Recombinant microorganism for the fermentative production of methionine |
EP2479279A1 (de) | 2011-01-20 | 2012-07-25 | Evonik Degussa GmbH | Verfahren zur fermentativen Herstellung schwefelhaltiger Aminosäuren |
CN110016484A (zh) | 2011-04-01 | 2019-07-16 | 味之素株式会社 | 用于产生l-半胱氨酸的方法 |
US9234223B2 (en) | 2011-04-01 | 2016-01-12 | Ajinomoto Co., Inc. | Method for producing L-cysteine |
AR086790A1 (es) * | 2011-06-29 | 2014-01-22 | Metabolic Explorer Sa | Un microorganismo para la produccion de metionina con importacion de glucosa mejorada |
CN104411821B (zh) | 2012-06-18 | 2017-08-08 | 代谢探索者公司 | 用于发酵生产甲硫氨酸的重组微生物 |
PL2700715T3 (pl) | 2012-08-20 | 2019-03-29 | Evonik Degussa Gmbh | Sposób fermentacyjnego wytwarzania L-aminokwasów z zastosowaniem ulepszonych szczepów z rodziny Enterobacteriaceae |
EP2762571A1 (de) | 2013-01-30 | 2014-08-06 | Evonik Industries AG | Mikroorganismus und Verfahren zur fermentativen Herstellung von Aminosäuren |
PL3039153T3 (pl) | 2013-08-30 | 2019-02-28 | Evonik Degussa Gmbh | Mikroorganizm do wytwarzania metioniny o ulepszonej aktywności syntazy metioniny i wypływie metioniny |
EP3189150A1 (en) | 2014-09-01 | 2017-07-12 | Metabolic Explorer | Method and microorganism for methionine production by fermentation with improved methionine efflux |
PL3331998T3 (pl) | 2015-08-07 | 2020-12-28 | Evonik Operations Gmbh | Wytwarzanie przez fermentację l-metioniny zależne od tiokarboksylanu białka |
FR3041659B1 (fr) | 2015-09-30 | 2017-10-20 | Arkema France | Procede de production de l-methionine |
FR3041658B1 (fr) | 2015-09-30 | 2017-10-20 | Arkema France | Procede de production de l-methionine |
CN108291243A (zh) | 2015-11-27 | 2018-07-17 | 赢创德固赛有限公司 | 生产l-甲硫氨酸的方法 |
EP3296404A1 (en) * | 2016-09-15 | 2018-03-21 | Evonik Degussa GmbH | Modified microorganism for production of methionine |
KR102472558B1 (ko) * | 2019-06-28 | 2022-12-01 | 씨제이제일제당 주식회사 | 황 함유 아미노산 또는 그 유도체 제조방법 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001070776A2 (en) | 2000-03-10 | 2001-09-27 | Trustees Of Tufts College | Nimr compositions and their methods of use |
JP4682454B2 (ja) * | 2000-06-28 | 2011-05-11 | 味の素株式会社 | 新規変異型n−アセチルグルタミン酸合成酵素及びl−アルギニンの製造法 |
DE10144493A1 (de) * | 2001-09-11 | 2003-07-03 | Degussa | Verfahren zur fermentativen Herstellung von L-Aminosäuren unter Verwendung coyneformer Bakterien |
DE102004013503A1 (de) * | 2004-03-18 | 2005-10-06 | Degussa Ag | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung coryneformer Bakterien |
DE102004055414A1 (de) * | 2004-11-17 | 2006-05-24 | Degussa Ag | Allele des metK-Gens aus coryneformen Bakterien |
US8399214B2 (en) * | 2005-07-18 | 2013-03-19 | Evonik Degussa Gmbh | Use of dimethyl disulfide for methionine production in microoraganisms |
EP1915445A2 (en) * | 2005-08-20 | 2008-04-30 | Scarab Genomics, LLC | Reduced genome e. coli |
DE602006019763D1 (de) * | 2005-10-31 | 2011-03-03 | Evonik Degussa Gmbh | Mikroorganismus und verfahren zur herstellung von l-methionin |
US8389250B2 (en) * | 2006-01-04 | 2013-03-05 | Metabolic Explorer | Methods for producing methionine by culturing a microorganism modified to enhance production of cysteine |
WO2009043372A1 (en) * | 2007-10-02 | 2009-04-09 | Metabolic Explorer | Increasing methionine yield |
WO2010020289A1 (en) * | 2008-08-22 | 2010-02-25 | Metabolic Explorer | Production of n-acetylated sulphur-containing amino acids with microorganisms having enhanced n-acetyltransferase enzymatic activity |
-
2008
- 2008-08-22 WO PCT/EP2008/061005 patent/WO2010020290A1/en active Application Filing
-
2009
- 2009-02-12 US US12/370,422 patent/US8748136B2/en active Active
- 2009-08-21 MX MX2011001962A patent/MX2011001962A/es active IP Right Grant
- 2009-08-21 AR ARP090103230A patent/AR073113A1/es unknown
- 2009-08-21 PL PL09782063T patent/PL2326724T3/pl unknown
- 2009-08-21 CN CN201410478758.6A patent/CN104293845A/zh active Pending
- 2009-08-21 RU RU2011108705/10A patent/RU2011108705A/ru not_active Application Discontinuation
- 2009-08-21 BR BRPI0917192-4A2A patent/BRPI0917192A2/pt active IP Right Grant
- 2009-08-21 KR KR1020117006419A patent/KR101660060B1/ko active IP Right Grant
- 2009-08-21 CN CN2009801419503A patent/CN102203270A/zh active Pending
- 2009-08-21 EP EP09782063.3A patent/EP2326724B1/en not_active Not-in-force
- 2009-08-21 JP JP2011523426A patent/JP5805533B2/ja not_active Expired - Fee Related
- 2009-08-21 MY MYPI2011000771A patent/MY174404A/en unknown
- 2009-08-21 WO PCT/EP2009/060811 patent/WO2010020681A1/en active Application Filing
- 2009-08-21 ES ES09782063T patent/ES2739466T3/es active Active
Non-Patent Citations (4)
Title |
---|
ANNE DURAND ET AL: "Rat kidney acylase I: further characterisation and mutation studies on the involvement of Glu 147 in the catalytic process", BIOCHIMIE, vol. 85, no. 10, 1 October 2003 (2003-10-01), pages 953 - 962, XP055212676, ISSN: 0300-9084, DOI: 10.1016/j.biochi.2003.09.002 * |
BABA TOMOYA ET AL: "Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection", MOLECULAR SYSTEMS BIOLOGY, THE MACMILLAN BUILDING, LONDON, GB, vol. 2, 1 February 2006 (2006-02-01), XP002519600, ISSN: 1744-4292, [retrieved on 20060221], DOI: 10.1038/MSB4100050 * |
PITTELKOW S ET AL: "Human and Porcine Aminoacylase I Overproduced in a Baculovirus Expression Vector System: Evidence for Structural and Functional Identity with Enzymes Isolated from Kidney", PROTEIN EXPRESSION AND PURIFICATION, ACADEMIC PRESS, SAN DIEGO, CA, vol. 12, no. 2, 1 March 1998 (1998-03-01), pages 269 - 276, XP004447549, ISSN: 1046-5928, DOI: 10.1006/PREP.1997.0816 * |
TOMOYA BABA ET AL: "Supplementary Table 3. Information on Keio collection deletion (excerpt)", MOLECULAR SYSTEMS BIOLOGY, VOL. 2, ISSUE 1, SUPPLEMENTARY INFORMATION, 21 February 2006 (2006-02-21), XP055212832, Retrieved from the Internet <URL:http://msb.embopress.org/content/2/1/2006.0008> [retrieved on 20150911] * |
Also Published As
Publication number | Publication date |
---|---|
CN104293845A (zh) | 2015-01-21 |
PL2326724T3 (pl) | 2019-11-29 |
MY174404A (en) | 2020-04-16 |
ES2739466T3 (es) | 2020-01-31 |
US20100047879A1 (en) | 2010-02-25 |
CN102203270A (zh) | 2011-09-28 |
US8748136B2 (en) | 2014-06-10 |
EP2326724A1 (en) | 2011-06-01 |
MX2011001962A (es) | 2011-03-21 |
BRPI0917192A2 (pt) | 2015-02-18 |
RU2011108705A (ru) | 2012-09-27 |
JP2012500622A (ja) | 2012-01-12 |
WO2010020681A1 (en) | 2010-02-25 |
KR20110046542A (ko) | 2011-05-04 |
AR073113A1 (es) | 2010-10-13 |
WO2010020290A1 (en) | 2010-02-25 |
JP5805533B2 (ja) | 2015-11-04 |
KR101660060B1 (ko) | 2016-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2326724B1 (en) | Producing methionine without n-acyl-methionine | |
EP2314710B1 (en) | Method for the production of methionine by culturing a microorganism modified to enhance production of cysteine | |
EP2205754B1 (en) | Increasing methionine yield | |
EP2861726B1 (en) | Recombinant microorganism for the fermentative production of methionine | |
US20080286840A1 (en) | Microorganisms Comprising Enzymes Express with Low Gamma-Elimination Activity | |
EP3039120B1 (en) | A microorganism for methionine production with enhanced methionine efflux | |
KR101770150B1 (ko) | 메티오닌 히드록시 유사체 (mha)의 발효 생산 | |
BRPI0917192B1 (pt) | Produção de metionina sem n-acil-metionina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110316 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20150918 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: EVONIK DEGUSSA GMBH |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20190128 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602009058506 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1136137 Country of ref document: AT Kind code of ref document: T Effective date: 20190615 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190522 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190922 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190522 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190522 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190522 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190822 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190522 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190823 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190822 |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: EVONIK OPERATIONS GMBH |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1136137 Country of ref document: AT Kind code of ref document: T Effective date: 20190522 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R081 Ref document number: 602009058506 Country of ref document: DE Owner name: EVONIK OPERATIONS GMBH, DE Free format text: FORMER OWNER: EVONIK DEGUSSA GMBH, 45128 ESSEN, DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190522 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190522 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190522 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190522 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190522 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190522 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2739466 Country of ref document: ES Kind code of ref document: T3 Effective date: 20200131 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602009058506 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190522 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190522 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190522 |
|
26N | No opposition filed |
Effective date: 20200225 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20190822 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190522 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190522 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190831 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190831 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190821 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20190831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190821 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190822 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190831 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: HC Owner name: EVONIK OPERATIONS GMBH; DE Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME; FORMER OWNER NAME: EVONIK DEGUSSA GMBH Effective date: 20200928 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190522 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190922 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20090821 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190522 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20210819 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20210819 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PL Payment date: 20210812 Year of fee payment: 13 Ref country code: DE Payment date: 20210819 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20211025 Year of fee payment: 13 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190522 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602009058506 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20220901 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220901 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220831 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230301 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20230929 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220822 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220821 |